Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when VTRS files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Departure of CFO (new) — CFO Theodora Mistras is departing to pursue another professional opportunity, though the company explicitly stated no disagreement on accounting or financial matters.
Viatris CFO Theodora Mistras resigns to pursue new opportunity; CAO Paul Campbell named interim
Filed May 4, 2026 · Period ending May 1, 2026 · ~1 min read
Key Changes
-
high
CFO Theodora Mistras voluntarily resigned effective May 8, 2026 to pursue another professional opportunity. She will remain employed through May 22 for transition purposes. The company explicitly stated her departure was not related to any disagreement on accounting, financial statements, internal controls, or operations.
Item 5.02 verify on EDGAR → -
high
Paul Campbell, current Chief Accounting Officer and Corporate Controller, appointed interim CFO effective May 8, 2026. Campbell has been with Viatris since the 2020 Mylan-Pfizer Upjohn combination and with Mylan since 2002 in roles of increasing responsibility.
Item 5.02 verify on EDGAR → -
medium
Mistras will not receive severance or accelerated equity vesting. She is eligible only for a pro-rated 2026 bonus based on actual performance capped at target, contingent on providing a release of claims and complying with restrictive covenants.
Item 5.02 verify on EDGAR →
Summary
Viatris disclosed that CFO Theodora Mistras voluntarily resigned effective May 8, 2026 to pursue another professional opportunity. The company took care to explicitly state that her departure was not related to any disagreement on accounting practices, financial statements, internal controls, or operations—language that typically signals a clean separation.
She will remain employed through May 22 for transition purposes. Paul Campbell, the company's Chief Accounting Officer and Corporate Controller since the 2020 Mylan-Pfizer Upjohn combination, will serve as interim CFO while the board searches for a permanent replacement. Campbell's 24-year tenure with the predecessor organization (Mylan since 2002) suggests continuity in financial leadership during the transition.
The departure terms are standard: no severance or accelerated vesting, with only a pro-rated bonus contingent on performance and customary restrictive covenants. Retail investors should monitor upcoming earnings calls and SEC filings for any indication of strategic shifts or financial reporting changes under new leadership. The timeline for appointing a permanent CFO and whether the company looks internally or externally will signal management's confidence in current strategy versus desire for fresh perspective.
Section-by-Section Diff
Event · Item 7.01 — Regulation FD Disclosure
Viatris announced a Chief Financial Officer transition effective May 1, 2026.
Added in current filing · verify on EDGAR →
On May 4, 2026, the Company issued a press release announcing the Chief Financial Officer transition.
Viatris disclosed a transition in the Chief Financial Officer role. CFO changes can signal strategic shifts, financial challenges, or normal succession planning. The 8-K does not provide details about whether this is a resignation, retirement, or planned succession, nor does it identify the incoming or outgoing CFO.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 16, 2026 · How we verify